CN101045155A - 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法 - Google Patents
用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法 Download PDFInfo
- Publication number
- CN101045155A CN101045155A CNA2007100789192A CN200710078919A CN101045155A CN 101045155 A CN101045155 A CN 101045155A CN A2007100789192 A CNA2007100789192 A CN A2007100789192A CN 200710078919 A CN200710078919 A CN 200710078919A CN 101045155 A CN101045155 A CN 101045155A
- Authority
- CN
- China
- Prior art keywords
- treatment
- cetrorelix
- antagonist
- give
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002357 endometrial effect Effects 0.000 title claims abstract description 23
- 230000001684 chronic effect Effects 0.000 title claims abstract description 15
- 208000000450 Pelvic Pain Diseases 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title abstract description 19
- 230000001225 therapeutic effect Effects 0.000 title abstract description 4
- 206010065789 Fallopian tube obstruction Diseases 0.000 title abstract 2
- 208000030843 hydrosalpinx Diseases 0.000 title abstract 2
- 230000035755 proliferation Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 claims abstract description 101
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 230000001939 inductive effect Effects 0.000 claims description 52
- 108700008462 cetrorelix Proteins 0.000 claims description 22
- 229960003230 cetrorelix Drugs 0.000 claims description 20
- 230000003442 weekly effect Effects 0.000 claims description 20
- 210000004291 uterus Anatomy 0.000 claims description 13
- 206010020880 Hypertrophy Diseases 0.000 claims description 12
- 210000003101 oviduct Anatomy 0.000 claims description 11
- 230000002354 daily effect Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 5
- 230000003203 everyday effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 3
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 2
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 2
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 2
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims 13
- 239000002474 gonadorelin antagonist Substances 0.000 abstract description 112
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 abstract description 79
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 34
- 239000003433 contraceptive agent Substances 0.000 abstract description 22
- 230000002254 contraceptive effect Effects 0.000 abstract description 22
- 229940127234 oral contraceptive Drugs 0.000 abstract description 22
- 239000003539 oral contraceptive agent Substances 0.000 abstract description 22
- 230000000202 analgesic effect Effects 0.000 abstract description 20
- 239000003098 androgen Substances 0.000 abstract description 18
- 229960003604 testosterone Drugs 0.000 abstract description 18
- 239000013543 active substance Substances 0.000 abstract 2
- 239000003435 antirheumatic agent Substances 0.000 abstract 2
- 230000003637 steroidlike Effects 0.000 abstract 2
- 150000003515 testosterones Chemical class 0.000 abstract 2
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 abstract 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 238000011419 induction treatment Methods 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 description 24
- 230000003213 activating effect Effects 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 18
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 13
- 229930182833 estradiol Natural products 0.000 description 13
- 229960005309 estradiol Drugs 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- KFEFLCOCAHJBEA-ANRVCLKPSA-N cetrorelix acetate Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KFEFLCOCAHJBEA-ANRVCLKPSA-N 0.000 description 9
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 8
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 230000011599 ovarian follicle development Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 235000012208 gluconic acid Nutrition 0.000 description 6
- 239000000174 gluconic acid Substances 0.000 description 6
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 5
- KATZUZNTRINHDT-HALMFYTRSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KATZUZNTRINHDT-HALMFYTRSA-N 0.000 description 5
- 108010023617 abarelix Proteins 0.000 description 5
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 5
- 229960002184 abarelix Drugs 0.000 description 5
- 108010070670 antarelix Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001076 estrogenic effect Effects 0.000 description 5
- 108700032141 ganirelix Proteins 0.000 description 5
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 5
- 229960003794 ganirelix Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 108010083551 iturelix Proteins 0.000 description 5
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000025661 ovarian cyst Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000583 progesterone congener Substances 0.000 description 5
- 150000003431 steroids Chemical class 0.000 description 5
- 229950011372 teverelix Drugs 0.000 description 5
- 208000005641 Adenomyosis Diseases 0.000 description 4
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 4
- 229960000766 danazol Drugs 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 201000009274 endometriosis of uterus Diseases 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 201000006828 endometrial hyperplasia Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- DPYIXBFZUMCMJM-BTJKTKAUSA-N (z)-but-2-enedioic acid;ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate Chemical compound OC(=O)\C=C/C(O)=O.N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 DPYIXBFZUMCMJM-BTJKTKAUSA-N 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical group C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000002357 laparoscopic surgery Methods 0.000 description 2
- 229960001910 lynestrenol Drugs 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000037324 pain perception Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RPGGYYVWJTWVMS-ZPSVQYCPSA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-10,13-dimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPGGYYVWJTWVMS-ZPSVQYCPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000029312 Muscular tumor Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960001865 cetrorelix acetate Drugs 0.000 description 1
- 229940112106 cetrotide Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000037416 cystogenesis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 229960003667 flupirtine Drugs 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 229940083461 halotestin Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15547899P | 1999-09-23 | 1999-09-23 | |
| US60/155,478 | 1999-09-23 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00813196A Division CN1376070A (zh) | 1999-09-23 | 2000-09-20 | 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101045155A true CN101045155A (zh) | 2007-10-03 |
Family
ID=22555601
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007100789192A Pending CN101045155A (zh) | 1999-09-23 | 2000-09-20 | 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法 |
| CN00813196A Pending CN1376070A (zh) | 1999-09-23 | 2000-09-20 | 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00813196A Pending CN1376070A (zh) | 1999-09-23 | 2000-09-20 | 用于治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗阻的方法 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1214086A2 (hu) |
| JP (2) | JP2003509467A (hu) |
| KR (1) | KR100772852B1 (hu) |
| CN (2) | CN101045155A (hu) |
| AU (1) | AU769482B2 (hu) |
| BG (1) | BG66128B1 (hu) |
| BR (1) | BR0014198A (hu) |
| CA (1) | CA2383510A1 (hu) |
| HK (1) | HK1049117A1 (hu) |
| HU (1) | HUP0202741A3 (hu) |
| IL (1) | IL148185A0 (hu) |
| MX (1) | MXPA02002436A (hu) |
| NO (1) | NO331198B1 (hu) |
| NZ (1) | NZ534836A (hu) |
| PL (1) | PL201898B1 (hu) |
| RU (1) | RU2255759C2 (hu) |
| SK (1) | SK3752002A3 (hu) |
| TR (1) | TR200200738T2 (hu) |
| TW (1) | TWI267373B (hu) |
| UA (1) | UA73956C2 (hu) |
| WO (1) | WO2001021194A2 (hu) |
| ZA (1) | ZA200201374B (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10157628A1 (de) * | 2001-11-26 | 2003-06-12 | Zentaris Ag | Injektionslösung eines LHRH-Antagonisten |
| US7214662B2 (en) | 2001-11-27 | 2007-05-08 | Zentaris Gmbh | Injectable solution of an LHRH antagonist |
| CN102089320B (zh) | 2008-01-24 | 2015-11-25 | 埃斯佩兰斯医药公司 | 溶解结构域融合构建体及其制备和使用方法 |
| US20120053122A1 (en) * | 2009-01-22 | 2012-03-01 | Maatschap Interne Geneeskunde Rijnstate | Method for the prophylaxis or treatment of flushing |
| KR20210090298A (ko) | 2012-10-30 | 2021-07-19 | 에스퍼란스 파마슈티컬스, 인코포레이티드 | 항체/약물 컨쥬게이트 및 이의 사용 방법 |
| EP3384930A1 (en) | 2013-03-15 | 2018-10-10 | AbbVie Inc. | Compositions for use in treating heavy menstrual bleeding |
| JP2021531236A (ja) | 2018-04-19 | 2021-11-18 | アッヴィ・インコーポレイテッド | 重度の月経出血を治療する方法 |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5064939A (en) * | 1990-02-06 | 1991-11-12 | The Salk Institute For Biological Studies | Cyclic gnrh antagonists |
| SE9301606D0 (sv) * | 1993-05-07 | 1993-05-07 | Per-Christer Oden | Composition for the treatment of impaired hair growth |
| DE69515666T2 (de) * | 1994-07-22 | 2000-07-06 | Hampton Roads Medical College | VERWENDUNG VON GnRH-ANTAGONISTEN ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR BEHANDLUNG GONADEN-STEROID ABHÄNGIGER ERKRANKUNGEN |
| US5658884A (en) * | 1994-07-22 | 1997-08-19 | The Medical College Of Hampton Roads | Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
| DE19513662A1 (de) * | 1995-04-08 | 1996-10-10 | Schering Ag | Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| WO1998009645A1 (fr) * | 1996-09-04 | 1998-03-12 | Dott Research Laboratory | Compositions medicamenteuses contenant des peptides, destinees a l'administration orale |
| WO1998055470A1 (en) * | 1997-06-05 | 1998-12-10 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
-
2000
- 2000-09-20 PL PL353244A patent/PL201898B1/pl not_active IP Right Cessation
- 2000-09-20 UA UA2002043346A patent/UA73956C2/uk unknown
- 2000-09-20 KR KR1020027003740A patent/KR100772852B1/ko not_active IP Right Cessation
- 2000-09-20 MX MXPA02002436A patent/MXPA02002436A/es active IP Right Grant
- 2000-09-20 IL IL14818500A patent/IL148185A0/xx not_active IP Right Cessation
- 2000-09-20 TR TR2002/00738T patent/TR200200738T2/xx unknown
- 2000-09-20 BR BR0014198-4A patent/BR0014198A/pt not_active Application Discontinuation
- 2000-09-20 CN CNA2007100789192A patent/CN101045155A/zh active Pending
- 2000-09-20 SK SK375-2002A patent/SK3752002A3/sk not_active Application Discontinuation
- 2000-09-20 EP EP00967722A patent/EP1214086A2/en not_active Withdrawn
- 2000-09-20 NZ NZ534836A patent/NZ534836A/en not_active IP Right Cessation
- 2000-09-20 RU RU2002111000/14A patent/RU2255759C2/ru not_active IP Right Cessation
- 2000-09-20 JP JP2001524618A patent/JP2003509467A/ja not_active Withdrawn
- 2000-09-20 CN CN00813196A patent/CN1376070A/zh active Pending
- 2000-09-20 HU HU0202741A patent/HUP0202741A3/hu unknown
- 2000-09-20 AU AU77792/00A patent/AU769482B2/en not_active Ceased
- 2000-09-20 CA CA002383510A patent/CA2383510A1/en not_active Abandoned
- 2000-09-20 WO PCT/EP2000/009212 patent/WO2001021194A2/en active IP Right Grant
- 2000-09-22 TW TW089119671A patent/TWI267373B/zh not_active IP Right Cessation
-
2002
- 2002-02-19 ZA ZA200201374A patent/ZA200201374B/en unknown
- 2002-03-21 NO NO20021430A patent/NO331198B1/no not_active IP Right Cessation
- 2002-04-05 BG BG106584A patent/BG66128B1/bg unknown
-
2003
- 2003-02-18 HK HK03101215.4A patent/HK1049117A1/zh unknown
-
2011
- 2011-10-17 JP JP2011227603A patent/JP2012051920A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SK3752002A3 (en) | 2003-06-03 |
| KR20020035879A (ko) | 2002-05-15 |
| BR0014198A (pt) | 2002-05-21 |
| IL148185A0 (en) | 2002-09-12 |
| HUP0202741A2 (hu) | 2003-01-28 |
| NZ534836A (en) | 2007-07-27 |
| JP2003509467A (ja) | 2003-03-11 |
| TWI267373B (en) | 2006-12-01 |
| MXPA02002436A (es) | 2003-02-12 |
| CA2383510A1 (en) | 2001-03-29 |
| ZA200201374B (en) | 2002-10-30 |
| WO2001021194A2 (en) | 2001-03-29 |
| TR200200738T2 (tr) | 2002-08-21 |
| UA73956C2 (en) | 2005-10-17 |
| PL201898B1 (pl) | 2009-05-29 |
| CN1376070A (zh) | 2002-10-23 |
| AU769482B2 (en) | 2004-01-29 |
| HUP0202741A3 (en) | 2003-12-29 |
| NO20021430D0 (no) | 2002-03-21 |
| JP2012051920A (ja) | 2012-03-15 |
| NO331198B1 (no) | 2011-10-31 |
| BG66128B1 (bg) | 2011-06-30 |
| BG106584A (bg) | 2003-02-28 |
| AU7779200A (en) | 2001-04-24 |
| KR100772852B1 (ko) | 2007-11-02 |
| WO2001021194A3 (en) | 2002-03-14 |
| PL353244A1 (en) | 2003-11-03 |
| NO20021430L (no) | 2002-05-07 |
| HK1049117A1 (zh) | 2003-05-02 |
| RU2255759C2 (ru) | 2005-07-10 |
| EP1214086A2 (en) | 2002-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zito et al. | Medical treatments for endometriosis-associated pelvic pain | |
| JP3130048B2 (ja) | エストロゲン依存症の治療 | |
| ES2281551T3 (es) | Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas. | |
| JP2012051920A (ja) | 子宮内膜組織の子宮外の増殖、慢性骨盤痛およびファロピウス管閉塞症を治療するための製剤学的組成物、前述の疾病を治療するための医薬を製造するためのｌｈｒｈアンタゴニスト又はｌｈｒｈアンタゴニストおよび活性剤の使用 | |
| JP5543920B2 (ja) | 閉経前の女性におけるエストロゲン依存症状の治療 | |
| Coutinho | Treatment of large fibroids with high doses of gestrinone | |
| US7666836B2 (en) | Method for the therapeutic management of endometriosis | |
| Bedaiwy et al. | Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists | |
| Kaminski et al. | Gynecological issues after organ transplantation | |
| JP2012077020A (ja) | ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬 | |
| ES2320662T3 (es) | Hormonoterapia restitutiva y tratamiento para la depresion con dienogest. | |
| US6689768B2 (en) | Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy | |
| EP0136781A2 (en) | Treatment of endometriosis | |
| JP3925688B2 (ja) | ＧｎＲＨａ治療中および／またはＧｎＲＨａ治療後の副作用を治療するための製薬学的調剤 | |
| RU2132189C1 (ru) | Способ лечения мастопатии и миомы матки | |
| Segal | Contraceptive innovations: needs and opportunities | |
| Østergaard | Employment of Androgens in Gynecology | |
| Swahn et al. | Various uses of mifepristone in gynaecology and obstetrics | |
| Prentice et al. | Medical management of endometriosis pain | |
| US20040167111A1 (en) | Pharmaceutical preparations for treating side effects during and/or after GnRHa therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1107262 Country of ref document: HK |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20071003 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1107262 Country of ref document: HK |